Item 8.01 Other Events.

--------------------------------------------------------------------------------

As previously reported by Sunesis Pharmaceuticals, Inc., or the Company, it had received a written notice from the Nasdaq Stock Market LLC, or Nasdaq, indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), or the Rule, as the Company's closing bid price for its common stock was below $1.00 per share for 30 consecutive business days.

On September 18, 2020, the Company received a letter from the Nasdaq Listing Qualifications Department notifying that the closing bid price of the Company's common stock has been at or above the minimum $1.00 per share for ten consecutive days. Accordingly, the Company had regained compliance with the Rule and the matter is now closed.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses